GENENTECH, INC for GENENTECH INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Monitor DrugSafety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
Copyright/Patent/Trademark CPT
Intellectual Property and Process Patent Issues - HR 1908. Patent Reform Act (all provisions); Cyber security , implementation of S.23: American Invents Act, Implementation of HR 1249; Transpacific partnership
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director Government Affairs |
| EVAN MORRIS | Vice President of Government Affairs |
Taxation/Internal Revenue Code TAX
FY14 appropriations bills, including issues related to FDA funding and drug approval/review oversight process; issues related to comprehensive tax U.S. corporations, and tax extenders, including R&D tax credit. S.3521, Family and Business Tax Cut Certanity Act of 2012 (tax "extenders"). Corporate tax reform issues. Fiscal cliff legislation. American Taxpayer relief act (HR 8); R&D Tax Credit issues; S. 3521, S.1577, Greater Research Opportunities with Tax Help Act: H.R. 942, American Research and Competitiveness Act of 2011; HR. 8; Research and Development Tax credit, year-end tax issues: Monitoring proposals on US tax treatment of foreign-owned US corporations;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director Government Affairs |
| ELI KOGAN | Asst. Director |
Health Issues HCR
Implementation of HR 1; Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus, issues relating to PDUFA, stimulus, issues relating to comparative effectiveness and CMS coverage of FDA approved therapies; issues related to the PPS rule involving stroke guidelines; Implementation of the the follow-on biologics in P.L. 1111-148 "Patient Protection and Affordable Care Act; FY13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577, S 3187; Pedigree and biologics issues; H.R. 905; ASP issues: H.R.5651; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Medicare prescription Drug and Modernization Act of 2003; Avastin use in breast cancer treatment; general patient reform issues; implementation of the Affordable Care of 2010; proposed cuts to Part B reimbursement; 340 B reimbursement policy; Medicare/Medicaid Reimbursement
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Sr. Director Government Affairs |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues related to the PPPS rule involving stroke guidelines. Proposals to reduce Medicare payment for Part B biologics. Concerns regarding Medicare payment policies for Biologics; issues relating to Prescription Drug User Fee Act and SP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 942- American Research & Competitiveness Act of 2011.; Medicare coverage and payment of Part B drugs and biologics; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; proposed cuts to Part B reimbursement; implementation of Health reform; Legislation for CMS.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director of Government Affairs |
| DARIN GARDNER | Sr. Director Government Affairs |
| EVAN MORRIS | Vice President of Government Affairs |
| KATHERINE RAAB | Director of Government Affairs |
Budget/Appropriations BUD
FY13 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HI/AID programs, hepatitis screening, care and treatment and access to breast cancer treatment; issues related to FDA &HHA program funding, FY13 Labor Health and Human Services and Education and related agencies appropriations bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director Government Affairs |
| ELI KOGAN | Asst. Director |
| EVAN MORRIS | Vice President of Government Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.